Skip to main content

Table 1 Demographic and baseline characteristics (safety population)

From: Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease

Characteristics N = 33
Race, n (%)  
  Caucasian 32 (97%)
  Hispanic or Latino 1 (3%)
Gender, n (%)  
  Male 19 (58%)
Age, years  
  Mean (SD) 59.0 (6.7)
  Median (Range) 58.1 (44–71)
Smoking Status, n (%)  
  Current Smoker 18 (55%)
Years Ago Quit, n 15
  Mean (SD) 10.2 (7.7)
  Median (Range) 9.5 (0–27)
Number of Years Smoked  
  Mean (SD) 38.6 (10.5)
  Median (Range) 40.0 (13–57)
FEV1, L/sec, prebronchodilator  
  Mean (SD) 1.6 (0.5)
  Median (Range) 1.5 (0.9–3.0)
FEV1, % predicted, prebronchodilator  
  Mean (SD) 50.5 (9.9)
  Median (Range) 47.3 (35.5–69.3)
FEV1, % predicted, postbronchodilator  
  Mean (SD) 60.6 (10.3)
  Median (Range) 57.6 (43.0–80.5)
  1. FEV1 = forced expiratory volume in 1 second; SD = standard deviation; L=liter